Movatterモバイル変換


[0]ホーム

URL:


AU2003289716A1 - Molecules for diagnostics and therapeutics - Google Patents

Molecules for diagnostics and therapeutics

Info

Publication number
AU2003289716A1
AU2003289716A1AU2003289716AAU2003289716AAU2003289716A1AU 2003289716 A1AU2003289716 A1AU 2003289716A1AU 2003289716 AAU2003289716 AAU 2003289716AAU 2003289716 AAU2003289716 AAU 2003289716AAU 2003289716 A1AU2003289716 A1AU 2003289716A1
Authority
AU
Australia
Prior art keywords
therapeutics
diagnostics
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003289716A
Other versions
AU2003289716A8 (en
Inventor
Christina M. Altus
Scott B. Anderson
Alan P. Au
Steven C. Banville
John L. Blanchard
Christopher M. Bruns
Angelo M. Delegeane
Linda V. Elder
Jr. Edward H. Gerstin
Darryl Gietzen
Toinette A. Harthshorne
Bonnie L. Hurwitz
Jennifer L. Jackson
Edward S. Kirton
Mary KWONG
Robert E. Lagace
Yan Ma
Mirjana M. Marjanovic
Elizabeth M. Mooney
Iqbal S. Panesar
Scott R. Panzer
Srikanth PATURY
Careyna H. Peralta
Steven J. Pitts
Jennifer L. Policky
Thirupathi P. Reddy
Pierre RIOUX
Jeanette P. Schmidt
Edward J. Shen
Fan Shen
Xiaobing SHI
Peter A. Spiro
Kristian A. Stevens
Elizabeth A. Stewart
Laura L. Stuve
Charlyn J. Suarez
Martin T. Suchorolski
Ursula A. Vitt
Xinhao Wang
James WINGROVE
Rachel J. Wright
Mingham C. Wu
Yuming Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte CorpfiledCriticalIncyte Corp
Publication of AU2003289716A1publicationCriticalpatent/AU2003289716A1/en
Publication of AU2003289716A8publicationCriticalpatent/AU2003289716A8/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

AU2003289716A2002-09-122003-09-12Molecules for diagnostics and therapeuticsAbandonedAU2003289716A1 (en)

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
US41026002P2002-09-122002-09-12
US41025902P2002-09-122002-09-12
US60/410,2592002-09-12
US60/410,2602002-09-12
PCT/US2003/028227WO2004023973A2 (en)2002-09-122003-09-12Molecules for diagnostics and therapeutics

Publications (2)

Publication NumberPublication Date
AU2003289716A1true AU2003289716A1 (en)2004-04-30
AU2003289716A8 AU2003289716A8 (en)2004-04-30

Family

ID=31997928

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU2003289716AAbandonedAU2003289716A1 (en)2002-09-122003-09-12Molecules for diagnostics and therapeutics

Country Status (2)

CountryLink
AU (1)AU2003289716A1 (en)
WO (1)WO2004023973A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20030114410A1 (en)2000-08-082003-06-19Technion Research And Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2003054141A2 (en)*2001-10-222003-07-03Children's Medical Center CorporationSperm-specific cation channel, catsper2, and uses therefor
AU2003243151A1 (en)*2002-08-162004-03-03Agensys, Inc.Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP1581641A4 (en)*2002-12-062006-11-15Diadexus IncCompositions, splice variants and methods relating to ovarian specific genes and proteins
US8871709B2 (en)*2003-02-052014-10-28Queensland University of TechnolgySynthetic chimeric proteins comprising epidermal growth factor and vitronectin
WO2004090097A2 (en)2003-04-032004-10-21Bristol-Myers Squibb CompanyPolynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
WO2004094623A2 (en)*2003-04-042004-11-04Incyte CorporationCell adhesion and extracellular matrix proteins
EP2332982A1 (en)*2003-05-142011-06-15Sumitomo Chemical Co., Ltd.Liver X receptor alpha splicing mutant protein, gene thereof and utilization of the same
MXPA06001329A (en)*2003-08-182006-05-04Wyeth CorpNOVEL HUMAN LXRalpha VARIANTS.
WO2005046454A2 (en)*2003-11-122005-05-26Trustrees Of The University Of PennsylvaniaMethods of using gelsolin to treat or prevent bacterial sepsis
US9408891B2 (en)2003-11-122016-08-09The Trustees Of The University Of PennsylvaniaMethods of using gelsolin to treat or prevent bacterial sepsis
ATE510020T1 (en)*2003-12-242011-06-15G2 Inflammation Pty Ltd TRANSGENIC NON-HUMAN MAMMAL WITH A POLYNUCLEOTIDE CODING FOR HUMAN-C5AR OR HUMANIZED C5AR
WO2005076012A2 (en)*2004-01-302005-08-18Five Prime Therapeutics, Inc.Novel splice variants and methods of use thereof
US20050186577A1 (en)2004-02-202005-08-25Yixin WangBreast cancer prognostics
US8124730B1 (en)2004-04-022012-02-28Bristol-Myers Squibb CompanyPolynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1586587A1 (en)*2004-04-162005-10-19Exonhit Therapeutics SACompositions and methods for detecting angiogenesis
CA2607686C (en)2004-05-122014-11-04Thomas P. StosselUse of gelsolin to treat infections
US20090004193A1 (en)*2004-07-232009-01-01Bayer Healthcare AgDiagnostics and Therapeutics for Diseases Associated With Vasoactive Intestinal Peptide Receptor 1 (Vpac1)
WO2006008008A2 (en)*2004-07-232006-01-26Bayer Healthcare AgDiagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
EP1802749B1 (en)*2004-10-212012-08-22Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders
EP2275547B1 (en)2004-12-132014-03-05Alethia Biotherapeutics Inc.Polynucleotides and polypeptide sequences involved in the process of bone remodeling
KR100664587B1 (en)*2004-12-222007-01-04김현기 Human cancer suppressor gene, protein encoded thereby, expression vector comprising the same and cells transformed with the vector
WO2006128902A1 (en)2005-06-012006-12-07Evotec Neurosciences GmbhDiagnostic and therapeutic target slc39a12 proteins for neurodegenerative diseases
EP1739092A1 (en)*2005-06-282007-01-03I.N.S.E.R.M. Institut National de la Sante et de la Recherche MedicalePeptidic antagonists of class III semaphorins/neuropilins complexes
CA2814598A1 (en)2005-09-122007-03-22The Regents Of The University Of MichiganRecurrent gene fusions in prostate cancer
US9957569B2 (en)2005-09-122018-05-01The Regents Of The University Of MichiganRecurrent gene fusions in prostate cancer
AU2014265023A1 (en)*2005-12-202014-12-04Sbi Biotech Co, Ltd.Anti-ILT7 Antibody
AU2012244391B2 (en)*2005-12-202014-09-11Sbi Biotech Co., Ltd.Anti-ILT7 antibody
HRP20130494T1 (en)*2005-12-202013-08-31Sbi Biotech Co., Ltd.Anti-ilt7 antibody
EP3936621A1 (en)*2006-01-202022-01-12Cell Signaling Technology, Inc.Translocation and mutant ros kinase in human non-small cell lung carcinoma
US8383799B2 (en)2006-01-202013-02-26Cell Signaling Technology, Inc.Translocation and mutant ROS kinase in human non-small cell lung carcinoma
WO2007089659A2 (en)*2006-01-262007-08-09Caprion Pharmaceutical, Inc.Tat-039 and methods of assessing and treating cancer
WO2007089783A2 (en)*2006-01-302007-08-09Caprion Pharmaceuticals, Inc.Tat-044 and methods of assessing and treating cancer
WO2007089793A2 (en)*2006-01-312007-08-09Caprion Pharmaceuticals, Inc.Tat-041 and methods of assessing and treating cancer
CA2680333C (en)2006-03-152016-10-25The Brigham And Women's Hospital, Inc.Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
JP5322917B2 (en)2006-03-152013-10-23ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Use of gelsolin for the diagnosis and treatment of inflammatory diseases
US7452985B2 (en)2006-08-172008-11-18Visgeneer, Inc.Human Ron-related gene variant associated with cancers
US9513296B2 (en)2006-08-212016-12-06Eidgenoessische Technische Hochschule ZurichSpecific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
EP1892248A1 (en)*2006-08-212008-02-27Eidgenössische Technische Hochschule ZürichSpecific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9689879B2 (en)2006-08-212017-06-27Eidgenoessische Technische Hochschule ZurichSpecific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
WO2008042814A2 (en)*2006-09-292008-04-10California Institute Of TechnologyMart-1 t cell receptors
EP2094307A4 (en)2006-11-082015-08-26Macrogenics West IncTes7 and antibodies that bind thereto
CA2692793C (en)2007-07-062014-05-20The Regents Of The University Of MichiganMipol1-etv1 gene rearrangements
ES2534490T3 (en)2007-08-022015-04-23Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
WO2009020521A2 (en)2007-08-032009-02-12The Brigham And Women's Hospital, Inc.Identification and treatment of estrogen responsive prostate tumors
US7892760B2 (en)2007-11-192011-02-22Celera CorporationLung cancer markers, and uses thereof
CA2711691A1 (en)*2008-01-072009-07-16Patrys LimitedBarb4 target, antibody designated barb4, barb4 related antibodies, and methods of making and using same
PT2708603T (en)2008-01-252017-07-20The Brigham And Women`S Hospital IncDiagnostic and therapeutic uses of gelsolin in renal failure
WO2009131605A2 (en)*2008-01-282009-10-29Thomas Jefferson UniversityFusion partner cell line for preparation of hybrid cells expressing human antibodies
EP2322610B1 (en)2008-07-162016-12-14Medical and Biological Laboratories Co., Ltd.Anti-human clcp1 antibody and use thereof
AU2013202393B2 (en)*2008-07-162015-01-22Institute For Research In BiomedicineHuman cytomegalovirus nuetralizing antibodies and use thereof
WO2010033294A1 (en)2008-09-222010-03-25Cedars-Sinai Medical CenterShort-form human md-2 as a negative regulator of toll-like receptor 4 signaling
US9512196B2 (en)2008-09-222016-12-06Cedars-Sinai Medical CenterShort-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
CA2751161C (en)*2008-12-302018-10-02Children's Medical Center CorporationMethod of predicting acute appendicitis
WO2010080769A2 (en)2009-01-062010-07-15Arresto Biosciences, Inc.Chemotherapeutic methods and compositions
AU2010226726B8 (en)2009-03-162014-08-14Pangu Biopharma LimitedCompositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
JP4495776B1 (en)*2009-07-302010-07-07日本製薬株式会社 Fusion protein
AU2010284036B2 (en)2009-08-212014-12-18Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
EP2478120B1 (en)2009-09-172015-09-02The Regents Of The University Of MichiganRecurrent gene fusions in prostate cancer
CA2781887C (en)2009-11-302018-03-27Genentech, Inc.Compositions and methods for the diagnosis and treatment of tumor
UA109888C2 (en)2009-12-072015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
US8828395B2 (en)2009-12-112014-09-09Atyr Pharma, Inc.Antibodies that bind tyrosyl-tRNA synthetases
ES2535951T3 (en)2009-12-112015-05-19Atyr Pharma, Inc. Histidyl tRNA synthetases to reduce inflammation
CN103154034B (en)2010-04-132016-06-08塞尔德克斯医疗公司Antibodies that bind human cd27 and uses thereof
US8946157B2 (en)*2010-05-032015-02-03Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
CA2804424C (en)2010-07-122021-03-30Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
AU2011293294B2 (en)2010-08-252016-03-24Pangu Biopharma LimitedInnovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
US20130303439A1 (en)*2010-09-302013-11-14Institut National De La Sante Et De La Recherche Medicale (Inserm)Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
US8945556B2 (en)2010-11-192015-02-03The Regents Of The University Of MichiganRAF gene fusions
US9714419B2 (en)2011-08-092017-07-25Atyr Pharma, Inc.PEGylated tyrosyl-tRNA synthetase polypeptides
CA2852629A1 (en)*2011-10-262013-05-02Nuclea Biotechnologies, Inc.Usp2a peptides and antibodies
WO2013123432A2 (en)2012-02-162013-08-22Atyr Pharma, Inc.Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
EP2845862B1 (en)2012-05-012018-11-21FUJIFILM CorporationMethod for incubating pluripotent stem cells and polypeptide to be used therefor
US10023640B2 (en)*2012-10-052018-07-17Kadmon Corporation, LlcHuman anti-VEGFR-2/KDR antibodies
AU2014236198A1 (en)2013-03-142015-10-15Bayer Healthcare LlcMonoclonal antibodies against antithrombin beta complexed with heparin
AU2014233436B2 (en)2013-03-152019-12-05Atyr Pharma, Inc.Histidyl-tRNA synthetase-Fc conjugates
JP6854246B2 (en)2015-06-082021-04-07アーケア ダイアグノスティクス リミテッド How to analyze urine sample
WO2016198835A1 (en)2015-06-082016-12-15Arquer Diagnostics LimitedMethods and kits
WO2017024137A1 (en)*2015-08-042017-02-09New York UniversityProgranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
US11072652B2 (en)2016-03-102021-07-27Viela Bio, Inc.ILT7 binding molecules and methods of using the same
PE20240693A1 (en)*2016-04-082024-04-10Immunocore Ltd T CELL RECEPTORS
US20240002459A1 (en)*2016-07-142024-01-04Emory UniversityGranulin Compositions and Uses Related Thereto
EP3612215B1 (en)2017-04-202024-08-28aTyr Pharma, Inc.Compositions for treating lung inflammation
CA3062591A1 (en)2017-05-082018-11-15Gritstone Oncology, Inc.Alphavirus neoantigen vectors
JP7348844B2 (en)2017-06-072023-09-21リジェネロン・ファーマシューティカルズ・インコーポレイテッド Compositions and methods for internalizing enzymes
KR20250096876A (en)*2017-07-312025-06-27리플렉션 바이오테크놀러지스 리미티드Cellular models of and therapies for ocular diseases
IL315325B1 (en)2018-01-042025-07-01Iconic Therapeutics IncAnti-tissue factor antibodies, antibody-drug conjugates, and related methods
US12258597B2 (en)2018-02-072025-03-25Regeneron Pharmaceuticals, Inc.Methods and compositions for therapeutic protein delivery
GB201803010D0 (en)*2018-02-262018-04-11Royal Holloway & Bedford New CollegeNeurodegenerative disorders
SG11202010011RA (en)2018-04-172020-11-27Celldex Therapeutics IncAnti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3793591A1 (en)2018-05-172021-03-24Regeneron Pharmaceuticals, Inc.Anti-cd63 antibodies, conjugates, and uses thereof
IL317797A (en)2019-05-302025-02-01Gritstone Bio IncModified adenoviruses
CN111859913B (en)*2020-06-122024-04-12北京百度网讯科技有限公司Processing method and device of wind control characteristic factors, electronic equipment and storage medium
JP2023541108A (en)2020-08-062023-09-28グリットストーン バイオ インコーポレイテッド Multi-epitope vaccine cassette
CA3213677A1 (en)*2021-03-302022-10-06Samir HanashCitrullinated proteins as biomarkers and therapy targets for cancer
AU2023326720A1 (en)2022-08-182025-04-03Immunocore LtdT cell receptor fusion proteins specific for mage a4
WO2024163607A2 (en)*2023-02-022024-08-08Board Of Regents, The University Of Texas SystemT-cell receptors targeting egfr and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20020119452A1 (en)*2000-01-182002-08-29Phippard Deborah J.Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells

Also Published As

Publication numberPublication date
WO2004023973A2 (en)2004-03-25
AU2003289716A8 (en)2004-04-30
WO2004023973A3 (en)2004-09-23

Similar Documents

PublicationPublication DateTitle
AU2003289716A1 (en)Molecules for diagnostics and therapeutics
AU2002344208A1 (en)Molecules for diagnostics and therapeutics
EP1552002A4 (en)Aptamer-toxin molecules and methods for using same
AU2003900780A0 (en)Analysis system and procedure
AU2003284238A1 (en)Indentation hardness test system
AU2003226094A1 (en)Compounds and methods
AUPS078002A0 (en)Dnazyme therapeutics
AU2003263521A1 (en)Polarizing arrangement
AU2003278578A1 (en)Molecules and methods using same for measuring non-transferrin bound iron
AU2003222120A1 (en)Oxon process
AU2003210518A1 (en)Molecules for diagnostics and therapeutics
AU2003288387A1 (en)Droplet - deposition related methods and apparatus
EP1572168A3 (en)Anti-infarction molecules
AUPS187002A0 (en)Condition-specific molecules and uses therefor
AU2003205627A1 (en)Diagnostics and therapeutics for diseases associated with gpr72
AU2002950242A0 (en)Screws
AU2003241466A1 (en)Surface-covering system and methods for making and using the same
AU2002305913A1 (en)Molecules for diagnostics and therapeutics
AU4018201A (en)Molecules for diagnostics and therapeutics
AU2001286964A1 (en)Molecules for diagnostics and therapeutics
AU2001241754A1 (en)Molecules for diagnostics and therapeutics
AU2003231740A1 (en)Compositions and methods for diagnostics and therapeutics for hydrocephalus
AUPS161602A0 (en)Novel molecules and uses therefor
AU2003283606A1 (en)Psoriasis diagnostics and therapeutics
AU2003239569A1 (en)Analyte microdetector and methods for use

Legal Events

DateCodeTitleDescription
MK6Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase

[8]ページ先頭

©2009-2025 Movatter.jp